Clidinium bromide

CAS No. 3485-62-9

Clidinium bromide( Ro 2-3773 )

Catalog No. M14193 CAS No. 3485-62-9

Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 42 In Stock
200MG 61 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Clidinium bromide
  • Note
    Research use only, not for human use.
  • Brief Description
    Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract.
  • Description
    Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome. (In Vivo):Clidinium (oral gavage; 0.25, 0.5, and 1 mg/kg; 3 days) causes constipation in mice. It leads to a significant decrease in %transit after clidinium treatment [(F(3, 28)=27.405] in mice.Clidinium (oral gavage; 0.25, 0.5, and 1 mg/kg; 3 days) has a significant effect on the clonic seizure threshold induced by intravenous PTZ which received clidinium (0.25, 0.5, and 1 mg/kg) [(F(3, 35) = 14.103].
  • In Vitro
    ——
  • In Vivo
    Clidinium (oral gavage; 0.25, 0.5, and 1 mg/kg; 3 days) causes constipation in mice. It leads to a significant decrease in %transit after clidinium treatment [(F(3, 28)=27.405] in mice.Clidinium (oral gavage; 0.25, 0.5, and 1 mg/kg; 3 days) has a significant effect on the clonic seizure threshold induced by intravenous PTZ which received clidinium (0.25, 0.5, and 1 mg/kg) [(F(3, 35) = 14.103]. Animal Model:Male NMRI mice weighing 20-25 g Dosage:0.25, 0.5, and 1 mg/kg Administration:Oral gavage; 0.25, 0.5, and 1 mg/kg; 3 days Result:Decreased the clonic seizure latency compared with control animals.
  • Synonyms
    Ro 2-3773
  • Pathway
    Endocrinology/Hormones
  • Target
    AChR
  • Recptor
    mAChR
  • Research Area
    Neurological Disease
  • Indication
    ——

Chemical Information

  • CAS Number
    3485-62-9
  • Formula Weight
    432.35
  • Molecular Formula
    C22H26BrNO3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: 10 mM
  • SMILES
    C[N+]12CCC(CC1)C(C2)OC(=O)C(C3=CC=CC=C3)(C4=CC=CC=C4)O.[Br-]
  • Chemical Name
    (1-methyl-1-azoniabicyclo[2.2.2]octan-3-yl) 2-hydroxy-2,2-diphenylacetate;bromide

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Pathak A, et al. J Chromatogr Sci. 2010 Mar;48(3):235-9.
molnova catalog
related products
  • TTNPB

    TTNPB, a potent RAR agonist, inhibits binding of [3H]tRA of human RARα (IC50: 5.1 nM), β (IC50: 4.5 nM), and γ (IC50: 9.3 nM), respectively.

  • Tolterodine tartrate

    Tolterodine Tartrate(PNU-200583E; Kabi-2234) is a potent muscarinic receptor antagonists that show selectivity for the urinary bladder over salivary glands in vivo.

  • Benzenesulfonamide

    Benzenesulfonamide ia an inhibitor of carbonic anhydrases.